COG Cambridge Cognition Holdings Plc

TIDMCOG

RNS Number : 8271F

Cambridge Cognition Holdings PLC

24 March 2022

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Appointment of Nominated Adviser and Joint Broker

Director Disclosures

Cambridge Cognition Holdings (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the appointment of Panmure Gordon (UK) Limited ("Panmure Gordon") as the Company's Nominated Adviser and Joint Broker with immediate effect.

The Company also announces the information in the Appendix below relating to additional director disclosures under Schedule Two, Paragraph (g) of the AIM Rules for Companies.

For further information, contact:

 
 Cambridge Cognition Holdings Plc              Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer        press@camcog.com 
  Steven Powell, Chairman 
 Panmure Gordon (NOMAD and Joint Broker)       Tel: 020 7886 2500 
  Freddy Crossley / Emma Earl / Mark Rogers     (Corporate Advisory) 
  Rupert Dearden                                (Corporate Broking) 
 Dowgate Capital Limited (Joint Broker)        Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

Appendix

The Company announces the following information relating to directors' disclosures pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies. At the time of the appointment of Debra Leeves and Richard Bungay to the Board of the Company on 1 July 2019 and 14 September 2020 respectively, the below disclosures were omitted:

Debra Leeves, Non-executive Director of the Company, held the following previous directorships within five years of her appointment to the Board of the Company:

   -      REX Bionics Europe Limited 
   -      Radcliffe Academy Trust 

Richard Bungay, Non-executive Director of the Company, was appointed a director of Glide Pharmaceutical Technologies Limited ("Glide") on 1 July 2014. On 31 August 2017, Lindsey Cooper and David Ronald Taylor of RSM Restructuring Advisory LLP were appointed as joint administrators of Glide Pharmaceutical Technologies Limited. A notice of progress report to 7 March 2018 and filed on 15 March 2018 indicated all unsecured creditor balances had been settled. The company was subsequently dissolved following liquidation on 20 October 2018.

Richard Bungay is also currently a director of the following companies:

   -      Diurnal Limited 
   -      Macrotarg Limited 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAPDDAANAEFA

(END) Dow Jones Newswires

March 24, 2022 03:01 ET (07:01 GMT)

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024